MAPT and Alzheimer disease: Even though the AppNL-G-F/NL-G-F mice significantly showed differences in compulsive/persistent behaviors compared with WT mice in phases 1 and 2, none of the AD clinical characteristics (e.g., tau pathology, severe neuronal loss, and memory-symptomatic cognition) was observed in AppNL-G-F/NL-G-F or other App KI mice (Saito et al., 2014; Sasaguri et al., 2017).